Litigation Details for BTG INTERNATIONAL LIMITED v. AMERIGEN PHARMACEUTICALS, INC. (D.N.J. 2016)
✉ Email this page to a colleague
BTG INTERNATIONAL LIMITED v. AMERIGEN PHARMACEUTICALS, INC. (D.N.J. 2016)
Docket | ⤷ Try a Trial | Date Filed | 2016-05-02 |
Court | District Court, D. New Jersey | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
Jury Demand | None | Referred To | William Clark |
Patents | 8,022,082; 8,822,438 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in BTG INTERNATIONAL LIMITED v. AMERIGEN PHARMACEUTICALS, INC.
Details for BTG INTERNATIONAL LIMITED v. AMERIGEN PHARMACEUTICALS, INC. (D.N.J. 2016)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-10-26 | 38 | associated with ZYTIGA.” (DTX 1276; 2T488:8-22). 82. A third marketing document explaining the …was a blocking patent in place. Prior to the ‘438 combination-therapy patent was the patent on abiraterone…abiraterone itself. That patent, U.S. Patent No. 5,604,213 (“the ‘213 patent”), titled “17-Substituted Steroids…blocking patent’ is an earlier patent that must be licensed in order to practice a later patent. This often…for infringement of United States Patent No. 8,822,438 (“the ‘438 patent”) brought by Janssen Biotech, Inc | External link to document | |
2018-10-31 | 43 | associated with ZYTIGA.” (DTX 1276; 2T488:8-22). 82. A third marketing document explaining the …was a blocking patent in place. Prior to the ‘438 combination-therapy patent was the patent on abiraterone…abiraterone itself. That patent, U.S. Patent No. 5,604,213 (“the ‘213 patent”), titled “17-Substituted Steroids…blocking patent’ is an earlier patent that must be licensed in order to practice a later patent. This often…for infringement of United States Patent No. 8,822,438 (“the ‘438 patent”) brought by Janssen Biotech, Inc | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |